Goals for 2001

www.amylin.com

• Acceptance of SYMLIN NDA for filing by FDA - 1Q

• Submit MAA in Europe - 2Q

• Completion of SYMLIN NDA review by FDA - 2H

Regulatory Review

• US launch of SYMLIN, pending FDA approval - 2H

Sales & Marketing

• AC2993 Phase 2 results - 2Q

• AC2993 to Phase 3 - 2H

• AC2993 LAR Phase 1 results - 3Q

• AC2993 LAR to Phase 2 - 2H

• AC3056 results - 2H

Clinical Studies

• AC2993 LAR to Phase 1 - 1Q

Product Development

• New product candidate - 2H

Drug Discovery

Previous slide

Back to first slide

View graphic version